Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells

Carneiro, Ângela; Falcão, Manuel; Pirraco, Ana; Milheiro–Oliveira, Paula; Falcão‐Reis, Fernando; Soares, Raquel

doi:10.1016/j.exer.2008.11.011

Cited by 57 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apesar de a literatura mostrar resultados diferentes no que se refere à concentração dos medicamentos, ela mostra-se concordante com a razão molar acima descrita (14,18) . Uma possível explicação para esses achados incompatíveis pode ser a diferença metodológica, entre os estudos: diferentes tipos celulares e diferentes técnicas para avaliar o efeito inibitório das drogas.…”

Section: Discussionunclassified

See 1 more Smart Citation

Comparação do efeito antiangiogênico do ranibizumab e do bevacizumab in vitro

Souto¹,

Maricato²,

Denapoli³

et al. 2011

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

RESUMOObjetivo: Comparar o efeito anti-angiogênico in vitro do Bevacizumab e do Ranibizumab. Métodos: Células endotelias venosas de cordão umbilical (ECV304), cultivadas em meio F12 com adição de 10% de soro fetal bovino, foram plaqueadas e tratadas com concentrações clinicamente relevantes de Bevacizumab e Ranibizumab. As drogas foram administradas logo após risco realizado no meio da cultura (metodologia de scratch). Medidas lineares do espaço livre de proliferação celular foram realizadas 24, 48 e 72 horas após o momento da realização do risco. Todos os experimentos foram realizados em triplicata e a análise estatística foi feita pelo teste T-student. Resultados: O efeito inibitório foi observado em ambas as drogas, apenas nas concentrações 0,5 e 0,7 mg/ml. Na concentração 0,7 mg/ml, o Ranibizumab demonstrou efeito inibitório maior do que o Bevacizumab. Na mesma concentração, o Ranibizumab foi três vezes mais potente que o Bevacizumab. O efeito inibitório foi observado apenas nas primeiras 24 horas para ambas as drogas. Conclusão: O Ranibizumab demonstrou efeito maior quando comparado com o Bevacizumab, porém tal efeito está mais relacionado à diferença na razão molar das drogas do que relacionada com uma diferença real no efeito anti-proliferativo. Descritores

show abstract

Section: Discussionunclassified

“…Como a bevacizumab e ranibizumab são drogas semelhantes é necessário avaliar se existe diferença na atividade terapêutica. Existem estudos comparativos dessas duas drogas in vitro (14) . Uma forma de medir este efeito é pela mensuração da capacidade inibitória da proliferação das células endoteliais.…”

Section: Introductionunclassified

Comparação do efeito antiangiogênico do ranibizumab e do bevacizumab in vitro

Souto¹,

Maricato²,

Denapoli³

et al. 2011

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

show abstract

“…Another in vitro study showed that bevacizumab and ranibizumab targeted several of the steps required during the angiogenic process, namely endothelial cell proliferation, migration and assembly into capillary-like structures 36 . Akova et al 37 (escrs.org/ vienna2011/programme/poster presentation) studied to determine and compare the effects of subconjunctival ranibizumab, bevacizumab and pegaptanib injections on CNV in a rat model.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Corneal Neovascularization by Subconjunctival Injection of Ranibizumab and Bevacizumab in Rabbit Cornea

Ekinci¹,

Çağatay²,

Yazar³

et al. 2013

Kafkas Univ Vet Fak Derg

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of subconjunctival ranibizumab and bevacizumab injection on angiogenesis in the rabbit cornea. The corneas of 24 New Zealand rabbits were cauterized with silver nitrate to induce neovascularization. The eyes were irrigated with 10 ml of 0.9% saline solution. The alkaline burns were similar in all the rabbits. At the 24 h after cauterization, the rabbits were divided into three groups of eight animals each: The first group (GC) received 0.02 ml 0.9% saline solution as a control group whereas second (GR) and third (GB) groups received 0.5 mg ranibizumab and 1.25 mg bevacizumab by subconjunctival injection, respectively, on days first and 7 after lesion. The rabbits' corneas were extracted on the 14th day. Digital photographs of the corneas were obtained and the newly formed vessels were analyzed in a computerized system (google sketch-up program). The rates of these vessels were compared between the groups. Ranibizumab and bevacizumab were both effective on inhibition of angiogenesis, in comparison to 0.9% saline solution (P<0.05). Ranibizumab was found to be statistically more effective to reduce corneal neovascularization than bevacizumab (P<0.05). Bevacizumab and ranibizumab were found to be effective in inhibiting the corneal neovascularization in the rabbit cornea. Ranibizumab seemed more effective than bevacizumab on inhibiting corneal neovascularization in the rabbit cornea. Keywords: Ranibizumab, Bevacizumab, Rabbit cornea, Corneal neovascularization, Angiogenesis Korneal Neovaskularizasyonun Subkonjonktival Ranibizumab ve Bevacizumab Enjeksiyonu ile Tavşan Korneasında İnhibisyonu ÖzetBu çalışmanın amacı; subkonjunktival olarak uygulanan ranibizumab and bevacizumab'ın tavşan korneasında anjiyogenezis üzerine etkilerini değerlendirmekti. Yirmi dört adet Yeni Zelanda tavşanının korneaları neovaskülarizasyon oluşturmak için gümüş nitrat ile koterize edildi. Gözler 10 ml %0.9 salin solusyonu ile yıkandı. Tüm gözlerde eşit miktarda kimyasal yanık oluşturulmasına dikkat edildi. Koterizasyon sonrası 24. saatte tavşanlar üç gruba ayrıldı: Kontrol grubuna (GC) (n=8) subkonjunktival 0.02 ml %0.9'luk salin solüsyonu; Grub Ranibizumab'a (GR) (n=8) subkonjunktival olarak 0.5 mg ranibizumab ve Grup Bevasizumab'a (GB) (n=8) ise subkonjunktival olarak 1.25 mg bevacizumab 1. ve 7. günlerde uygulandı Topical antibiotik tedavisi sonrası, tavşan korneaları 14. günde çıkarıldı. Korneaların digital fotoğrafları alınarak yeni oluşmuş damarlar bilgisayar programı (google sketch-up programı) yardımıyla analiz edildi. Yeni oluşan damar yapılarının alanının kornea alanına oranları gruplar arasında değerlendirildi. Ranibizumab ve Bevasizumab'ın her ikisi de anjiyogenez inhibisyonunda %0.9 salin solüsyonuna kıyasla (P<0.05) daha etkili olduğu saptandı.Ranibizumab'ın korneal neovaskülarizasyon azaltıcı etkisi Bevasizumab'tan istatistiksel olarak anlamlı (P<0.05) derecede fazla bulundu. Bevasizumab ve Ranibizumab'ın tavşan korneasında neovaskularizasyonu inhibe etmekte etkili olduğu tesp...

show abstract

“…Anti-VEGF therapy also inhibits proliferation, migration and promotes apoptosis of endothelial cells [115,116] and causes rapid regression of retinal neovascular tufts [112,114]. However, it has no action on hypoxia and on the stimuli that are leading to VEGF production.…”

Section: Anti-vegf Therapymentioning

confidence: 99%

Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options

Falcão¹

2012

TOCVJ

View full text Add to dashboard Cite

Diabetic retinopathy is the major cause of blindness at working age. The pathogenesis behind visual loss is related with retinal angiogenesis and increased retinal vascular permeability. These changes seem to be the result of chronic hyperglycemia and hypoxia. Several mechanisms have been proposed to cause the retinal and vasculature cellular damage. They include the formation of advanced end glycation products, aldose reductase activity and reactive oxygen species. Ultimately, they lead to the expression of VEGF-A. This growth factor seems to play the pivotal role in the development of the complications associated with the disease including break down of the inner blood retinal barrier, macular edema and vasoproliferation. Other mechanisms like inflammation, protein kinase C activity and erythropoietin have been strongly associated with the pathogenesis.Laser therapy is still the standard of care for diabetic retinopathy and prevents severe vision loss in 95% of patients if timely treatment is performed. The better understanding of the disease has led to the production of new management options that may become important adjuvants for the disease. They include intravitreal anti-VEGF therapy, intravitreal steroid therapy and systemic protein kinase C inhibitors. Vitrectomy is an important option for advanced cases of the disease such as tractional retinal detachment or non-absorbing vitreous hemorrhages.

show abstract

Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells

Cited by 57 publications

References 24 publications

Comparação do efeito antiangiogênico do ranibizumab e do bevacizumab in vitro

Comparação do efeito antiangiogênico do ranibizumab e do bevacizumab in vitro

Inhibition of Corneal Neovascularization by Subconjunctival Injection of Ranibizumab and Bevacizumab in Rabbit Cornea

Diabetic Retinopathy: Understanding Pathologic Angiogenesis and Exploring its Treatment Options

Contact Info

Product

Resources

About